Ligand Pharmaceuticals LGND Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accounts receivable?
- Ligand Pharmaceuticals (LGND) reported accounts receivable of $53.38M in Q1 2026.
- How has Ligand Pharmaceuticals's accounts receivable changed year-over-year?
- Ligand Pharmaceuticals's accounts receivable increased by 38.7% year-over-year, from $38.49M to $53.38M.
- What is the long-term trend for Ligand Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accounts receivable has grown at a 1.0% compound annual growth rate (CAGR), from $56.85M to $59.6M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.